Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, Kamada Ltd (NASDAQ: KMDA), plays an important role in helping address rare ...

Catalyst Pharmaceuticals Inc (CPRX) reports a robust 28.3% revenue increase in Q4 2024, driven by strong product performance ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Collegium Pharmaceutical (COLL – Research Report), ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – Research Report), ...

Tom Hughes is the founder and CEO of Virtual Science AI.

US health officials are reportedly reexamining a $590 million agreement awarded to Moderna (Nasdaq: MRNA) for the development ...

South Korean vaccine maker SK bioscience today revealed that it has received prior notification from the Pan American Health ...

Corneal Ulcer Treatment MarketThe global corneal ulcer treatment market is projected to grow at a CAGR of 5.2% from 2024 to 2034, reaching a market value of USD 1,601.1 million by 2034. In 2024, the ...